 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 June 1993 | Volume 118 Issue 11 | Pages 860-864
Objective: To identify and describe patients with hepatotoxicity possibly caused by flutamide, an antiandrogen drug.
Design: Case series of reports, submitted to the Adverse Drug Event Reporting System of the Food and Drug Administration.
Setting: Outpatient clinics and physicians' offices in the United States.
Patients: Nineteen patients treated with flutamide for prostate cancer or benign prostatic hypertrophy (for Investigation of a New Drug or off-label use).
Measurements: Evidence of increased liver enzyme levels, hyperbilirubinemia, associated clinical symptoms, and diagnoses of cholestatic hepatitis. Autopsy reports were used when available.
Results: From the time of marketing of flutamide in February 1989 through March 1991, the Food and Drug Administration received reports of 19 patients in the United States who developed serious hepatotoxicity while using flutamide. Fourteen patients had resolution of abnormal liver function test results after discontinuing or decreasing the dose of flutamide, but five patients died of progressive liver disease. Autopsy reports from three patients and abnormal pathologic results from three other patients (reported to the Food and Drug Administration or in the medical literature) showed hepatocellular necrosis and possibly cholestasis. Thorough work-ups excluded other possible causes than flutamide.
Conclusions: Flutamide appears to cause hepatotoxic effects in certain patients. Physicians should tell patients to immediately report to physicians nausea, vomiting, fatigue, jaundice, and other signs and symptoms of liver injury.
Author and Article Information
From the Food and Drug Administration, Rockville, Maryland; Oakland Naval Hospital, Oakland, California.
ARTICLE
Fatal and Nonfatal Hepatotoxicity Associated with Flutamide
Requests for Reprints: Reprints will not be available.
Acknowledgments: The authors thank the physicians and pharmacists who reported cases and additional information to the FDA and thank Traci Tate for secretarial assistance.
This article has been cited by other articles:
|
|
 |
|
  J. Calaf, E. Lopez, A. Millet, J. Alcaniz, A. Fortuny, O. Vidal, J. Callejo, F. Escobar-Jimenez, E. Torres, J. J. Espinos, et al. Long-Term Efficacy and Tolerability of Flutamide Combined with Oral Contraception in Moderate to Severe Hirsutism: A 12-Month, Double-Blind, Parallel Clinical Trial J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3446 - 3452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ibanez and F. de Zegher Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women Hum. Reprod. Update, May 1, 2006; 12(3): 243 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Willenberg, M. Bahlo, W. A. Scherbaum, F. de Zegher, D. B. Dunger, L. Ibanez, and R. L. Rosenfield Hirsutism. N. Engl. J. Med., April 6, 2006; 354(14): 1533 - 1535. [Full Text] [PDF]
|
|
|
|
|
|
M. Hero, O. A. Janne, K. Nanto-Salonen, L. Dunkel, and T. Raivio Circulating Antiandrogenic Activity in Children with Congenital Adrenal Hyperplasia during Peroral Flutamide Treatment J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5141 - 5145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ibanez, A. Jaramillo, A. Ferrer, and F. de Zegher Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women Hum. Reprod., July 1, 2005; 20(7): 1833 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibanez and F. de Zegher Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome Hum. Reprod., January 1, 2003; 18(1): 57 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ibáñez, N. Potau, M. V. Marcos, and F. de Zegher Treatment of Hirsutism, Hyperandrogenism, Oligomenorrhea, Dyslipidemia, and Hyperinsulinism in Nonobese, Adolescent Girls: Effect of Flutamide J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3251 - 3255. [Abstract] [Full Text]
|
|
|
|
|
|
D. P. Merke, M. F. Keil, J. V. Jones, J. Fields, S. Hill, and G. B. Cutler Jr. Flutamide, Testolactone, and Reduced Hydrocortisone Dose Maintain Normal Growth Velocity and Bone Maturation Despite Elevated Androgen Levels in Children with Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1114 - 1120. [Abstract] [Full Text]
|
|
|
|
|
|
P. Moghetti, F. Tosi, A. Tosti, C. Negri, C. Misciali, F. Perrone, M. Caputo, M. Muggeo, and R. Castello Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 89 - 94. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Cetin, D. Demirci, A. Unal, M. Altinbas, M. Guven, and K. Unluhizarci Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma Human and Experimental Toxicology, March 1, 1999; 18(3): 137 - 140. [Abstract] [PDF]
|
|
|
|
|
|
E. Diamanti-Kandarakis, A. Mitrakou, S. Raptis, G. Tolis, and A. J. Duleba The Effect of a Pure Antiandrogen Receptor Blocker, Flutamide, on the Lipid Profile in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2699 - 2705. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. G. McLeod Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer Oncologist, February 1, 1997; 2(1): 18 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Lee Drug-Induced Hepatotoxicity N. Engl. J. Med., October 26, 1995; 333(17): 1118 - 1127. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Diamanti-Kandarakis, G. Tolis, and A. J. Duleba Androgens and Therapeutic Aspects of Antiandrogens in Women Reproductive Sciences, July 1, 1995; 2(4): 577 - 592. [Abstract] [PDF]
|
|
Article
